Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis

Pharmacotherapy

Volumn 23, Issue 10 II, 2003, Pages 1322-1326

  DePestel, Daryl D ^a   Peloquin, Charles A ^b   Carver, Peggy L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; PERITONEAL DIALYSIS FLUID; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL PERITONITIS; CASE REPORT; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERANCE; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL DIALYSIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DIALYSIS SOLUTIONS; ENTEROCOCCUS FAECALIS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXAZOLIDINONES; PERITONEAL DIALYSIS; PERITONITIS; VANCOMYCIN RESISTANCE;

EID: 0141642151     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.12.1322.32702     Document Type: Article

References (17)

1. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000;44:1062-6.
2. Centers for Disease Control and Prevention. Staphylococcus aureus resistance to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7.
3. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus: Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002;51:902.
4. Bowker KE, Wootton M, Holt HA, MacGowan AP. In vitro activity of linezolid against gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients. J Antimicrob Chemother 2002;49:578-80.
5. Pharmacia & Upjohn. Zyvox (linezolid) package insert. Kalamazoo, MI; 2001.
6. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis. Presented at the 38th interscience conference on antimicrobial agents and chemotherapy, San Diego, CA, September 24-27, 1998.
7. Troidle L, Kliger AS, Gorban-Brennan N, Fikrig M, Golden M, Finkelstein FO. Nine episodes of CPD-associated peritonitis with vancomycin-resistant enterococci. Kidney Int 1996;50:1368-72.
8. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 1994;344:1025-6.
9. Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001;33:375-9.
10. Clemett D, Markham A. Linezolid. Drugs 2000;59:815-27.
11. Zurenko GE, Gibson JK, Shinabarger DL, Aristoff PA, Ford CW, Tarpley WG. Oxazolidinones: a new class of antibacterials. Curr Opin Pharmacol 2001;1:470-6.
12. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80.
13. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45:1843-6.
14. Rana B, Butcher I, Seaton RA, Murnaghan, C, Tobin C, Grigoris P. Linezolid penetration into osteoarticular tissues [abstr]. In: Program and abstracts of the annual meeting of the Infectious Diseases Society of America, Chicago, IL, October 24-27, 2002:56.
15. Gopal Rao G, Steger A, Tobin CM. Linezolid levels in pancreatic secretions. J Antimicrob Chemother 2001;48:931-2.
16. Gendjar SR, Moriyama B, Bailey EM, et al. Pharmacokinetics of oral linezolid in patients on peritoneal dialysis [abstr]. In: Proceedings of the American Society of Nephrology/International Society of Nephrology World Congress of Nephrology, San Francisco, CA, October 13-17, 2001:A2205.
17. Bailey M, Faber MD, Nafziger DA. Linezolid for the treatment of vancomycin-resistant enterococcal peritonitis. Am J Kidney Dis 2001; 38:1-3.